Abstract
Human immunodeficiency virus type 1 (HIV) infects macrophages and microglia in the CNS and frequently causes neurocognitive impairment. Although antiviral therapy generally reduces the viral load in the CNS and improves HIV-associated neurological dysfunction, most current antiviral drugs have poor CNS penetrance and cannot completely suppress viral replication. Furthermore, drug-resistance mutations can evolve independently in the CNS. Thus, a longlived viral reservoir persists in macrophages and microglia in the brain despite antiviral therapy. This review discusses mechanisms underlying the neurotropism of HIV, focusing on the role of the HIV envelope glycoproteins and their interactions with CD4 and the chemokine receptors CCR5 and CXCR4. We review data from studies of neurotropic HIV derived from the brains of patients with HIV-associated neurocognitive impairment as well as studies of nonhuman primate models. Understanding mechanisms that underlie HIV neurotropism and neurovirulence is critical for development of therapeutics to inhibit CNS infection and preventing neurological injury in HIV-infected individuals.
Keywords: HIV, CCR5, macrophages, microglia, neurotropism
Current HIV Research
Title: Mechanisms of HIV-1 Neurotropism
Volume: 4 Issue: 3
Author(s): Rebecca Dunfee, Elaine R. Thomas, Paul R. Gorry, Jianbin Wang, Petronela Ancuta and Dana Gabuzda
Affiliation:
Keywords: HIV, CCR5, macrophages, microglia, neurotropism
Abstract: Human immunodeficiency virus type 1 (HIV) infects macrophages and microglia in the CNS and frequently causes neurocognitive impairment. Although antiviral therapy generally reduces the viral load in the CNS and improves HIV-associated neurological dysfunction, most current antiviral drugs have poor CNS penetrance and cannot completely suppress viral replication. Furthermore, drug-resistance mutations can evolve independently in the CNS. Thus, a longlived viral reservoir persists in macrophages and microglia in the brain despite antiviral therapy. This review discusses mechanisms underlying the neurotropism of HIV, focusing on the role of the HIV envelope glycoproteins and their interactions with CD4 and the chemokine receptors CCR5 and CXCR4. We review data from studies of neurotropic HIV derived from the brains of patients with HIV-associated neurocognitive impairment as well as studies of nonhuman primate models. Understanding mechanisms that underlie HIV neurotropism and neurovirulence is critical for development of therapeutics to inhibit CNS infection and preventing neurological injury in HIV-infected individuals.
Export Options
About this article
Cite this article as:
Dunfee Rebecca, Thomas R. Elaine, Gorry R. Paul, Wang Jianbin, Ancuta Petronela and Gabuzda Dana, Mechanisms of HIV-1 Neurotropism, Current HIV Research 2006; 4 (3) . https://dx.doi.org/10.2174/157016206777709500
DOI https://dx.doi.org/10.2174/157016206777709500 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Impact of Latent Viral Infections in Mechanically Ventilated Patients
Current Respiratory Medicine Reviews Viral Proteases as Targets for Drug Design
Current Pharmaceutical Design Novel Opportunities to Study and Block Interactions between Viruses and Cell Surface Heparan Sulfates by using Dispirotripiperazines
Letters in Drug Design & Discovery Pharmacogenetics of the Metabolic Disturbances and Atherosclerosis Associated with Antiretroviral Therapy in HIV-Infected Patients
Current Pharmaceutical Design Regulatory Triangle of Neurodegeneration, Adult Neurogenesis and MicroRNAs
CNS & Neurological Disorders - Drug Targets Amygdalar Atrophy in Early Alzheimer’s Disease
Current Alzheimer Research Intracellular Restriction Factors In Mammalian Cells - An Ancient Defense System Finds A Modern Foe
Current HIV Research mRNA as a Versatile Tool for Exogenous Protein Expression
Current Gene Therapy Effective Antiviral Medicinal Plants and Biological Compounds Against Central Nervous System Infections: A Mechanistic Review
Current Drug Discovery Technologies Cell Surface Nucleolin as a Target for Anti-Cancer Therapies
Recent Patents on Anti-Cancer Drug Discovery Role of Ischemic Blood-Brain Barrier on Amyloid Plaques Development in Alzheimers Disease Brain
Current Neurovascular Research Understanding Helicases as a Means of Virus Control
Current Pharmaceutical Design VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future
Current Cancer Drug Targets From Mice to Macaques – Animal Models of HIV Nervous System Disease
Current HIV Research Biological Activity of Cytokines: An Evolutionary Perspective
Current Pharmaceutical Design Identification of Pyrazole Derivative as an Antiviral Agent Against Chikungunya Through HTVS
Letters in Drug Design & Discovery Neurophysiology of Sleep and Wakefulness: Basic Science and Clinical Implications
Current Neuropharmacology New Approaches to Chikungunya Virus Vaccine Development
Recent Patents on Inflammation & Allergy Drug Discovery Optimization on Fc for Improvement of Stability and Aggregation Resistance
Current Pharmaceutical Biotechnology Vaccine Safety Monitoring Systems in Developing Countries: An Example of the Vietnam Model
Current Drug Safety